Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer

被引：0
作者：
Shunji Takahashi
机构：
[1] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Medical Oncology
来源：
Journal of Bone and Mineral Metabolism | 2023年 / 41卷
关键词：
Breast cancer; Prostate cancer; Cancer-therapy induced bone loss; Bisphosphonates; Denosumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Breast cancer and prostate cancer are sex hormone-dependent cancers, and estrogen or androgen suppression therapy is the standard treatment. Cancer treatment-induced bone loss (CTIBL): bone loss and osteoporosis have become important side effects of these therapies. To summarize the current evidences, (1) Endocrine therapy for breast cancer and prostate cancer is associated with a significant decrease in bone mineral density. (2) Aromatase inhibitors (AI) for breast cancer are associated with a significant increase in fractures, and androgen deprivation therapy (ADT) for prostate cancer is likely to be associated with an increase in fractures. (3) Administration of bisphosphonates and denosumab increases bone mass in patients undergoing endocrine therapy for breast cancer. Administration of bisphosphonates, denosumab, and SERMs increased bone mass in patients undergoing ADT therapy for prostate cancer. (4) Bisphosphonates and denosumab reduce fracture risk in patients on AI for breast cancer, and toremifene and denosumab in patients on ADT for prostate cancer.
引用
收藏
页码：307 / 316
页数：9
相关论文
共 286 条
  • [1] Waqas K(2021)Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer J Bone Oncol 28 1451-1467
  • [2] Lima Ferreira J(1998)Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group Lancet 351 341-349
  • [3] Tsourdi E(2009)Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer J Natl Cancer Inst 101 509-518
  • [4] Hackshaw A(2010)Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 343-353
  • [5] Baum M(2001)Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials J Clin Oncol 19 2431-2442
  • [6] Fornander T(2003)Aromatase inhibitors in breast cancer N Engl J Med 348 817-827
  • [7] Dowsett M(2020)Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future Lancet 395 1571-1581
  • [8] Cuzick J(2021)Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Ann Oncol 32 78-84
  • [9] Ingle J(1996)Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women J Clin Oncol 14 107-118
  • [10] Klijn JG(2019)Incidence of fractures in young women with breast cancer—a retrospective cohort study J Bone Oncol 18 73-82
12345678910